Some excerpts from the article referencing just a tiny aspect of the hand and glove funding and technology development relationship of the clot shot from DARPA's desk to the pharmaceutical companies' labs:
>The first company in the United States to enter clinical trials with a vaccine for the virus was funded by DARPA. So was the second company. And the P3 program has already led to the world’s first study in humans of a potential covid-19 antibody treatment. If successful, antibody treatments would offer up to three months of immunity against covid-19. Unlike vaccines, they could also help heal people already infected with the virus.
>Some of the vaccines and antibodies linked to DARPA could be ready later this year, which would mark one of the speediest responses to a global pandemic in the history of medicine.
>By 2019, a project DARPA funded at the Massachusetts-based company Moderna demonstrated in a Phase 1 clinical trial that RNA could indeed deliver an antibody to humans and provide protection against the mosquito-borne virus chikungunya.
>In addition to Moderna, two other pharmaceutical companies — Pfizer and CureVac — are pursuing RNA vaccines, as is a small laboratory at Imperial College in London and the People’s Liberation Army Academy of Military Sciences in China. CureVac was also funded by DARPA.
